Blood Transfus. 2013 Oct 24:1-6. doi: 10.2450/2013.0303-12. [Epub ahead of print]

Comparison of in vitro responses to fresh whole blood and reconstituted whole blood after collagen stimulation.

Nepstad I, Reikvam H, Strandenes G, Hess JR, Apelseth TO, Hervig TA.

Br J Haematol. 2014 Jan;164(2):200-11. doi: 10.1111/bjh.12611. Epub 2013 Oct 23.

Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect.

Reikvam H, Tamburini J, Skrede S, Holdhus R, Poulain L, Ersvaer E, Hatfield KJ, Bruserud O.

Leuk Res Treatment. 2014;2014:143479. doi: 10.1155/2014/143479. Epub 2014 Jan 8.

In Vitro Characterization of Valproic Acid, ATRA, and Cytarabine Used for Disease-Stabilization in Human Acute Myeloid Leukemia: Antiproliferative Effects of Drugs on Endothelial and Osteoblastic Cells and Altered Release of Angioregulatory Mediators by Endothelial Cells.

Kvestad H, Evensen L, Lorens JB, Bruserud O, Hatfield KJ.

Leukemia. 2014 Feb 27. doi: 10.1038/leu.2014.89. [Epub ahead of print]

Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia.

Kontro M, Kuusanmäki H, Eldfors S, Burmeister T, Andersson EI, Bruserud O, Brümmendorf TH, Edgren H, Gjertsen BT, Itälä-Remes M, Lagsrtöm S, Lohi O, Lundán T, Martí JM, Majumder MM, Parsons A, Pemovska T, Rajala H, Vettenranta K, Kallioniemi O, Mustjoki S, Porkka K, Heckman CA.

Tidsskrift for den Norske laegeforening 2014 May 27;134:1052-5. Norwegian.

Akutt promyelocyttleukemi.

Reikvam H, Hovland R, Bruserud O.

Tidsskr Nor Laegeforen. 2014 May 27;134(10):1058-61. doi: 10.4045/tidsskr.13.0817. eCollection 2014.

[A man in his 80s with muscle stiffness and skin bleeding].

[Article in Norwegian]

Tvedt TH1, Holme PA2, Bruserud Ø1.

Mol Cancer. 2014 May 21;13:116. doi: 10.1186/1476-4598-13-116.

Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia.

Haaland I, Opsahl JA, Berven FS, Reikvam H, Fredly HK, Haugse R, Thiede B, McCormack E, Lain S, Bruserud O, Gjertsen BT1.

Expert Opin Ther Targets. 2014 Aug;18(8):929-44. doi: 10.1517/14728222.2014.924925. Epub 2014 Jun 24.

Heat shock protein 70 - the next chaperone to target in the treatment of human acute myelogenous leukemia?

Reikvam H1, Brenner AK, Nepstad I, Sulen A, Bruserud Ø.

Cancer Immunol Immunother. 2014 Aug;63(8):757-77. doi: 10.1007/s00262-014-1578-z. Epub 2014 Jul 5.

Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies.

Bruserud Ø1, Tvedt TH, Paulsen PQ, Ahmed AB, Gedde-Dahl T, Tjønnfjord GE, Slåstad H, Heldal D, Reikvam H.

Proteomics. 2014 Sep;14(17-18):1971-6. doi: 10.1002/pmic.201300448. Epub 2014 Aug 8.

Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines.

Aasebø E1, Vaudel M, Mjaavatten O, Gausdal G, Van der Burgh A, Gjertsen BT, Døskeland SO, Bruserud O, Berven FS, Selheim F.

Expert Opin Ther Targets. 2014 Sep 9:1-15. [Epub ahead of print]

Identification of a subset of patients with acute myeloid leukemia characterized by long-term in vitro proliferation and altered cell cycle regulation of the leukemic cells.

Hatfield KJ1, Reikvam H, Bruserud O.